Pinnacle Wealth Management Advisory Group LLC Lowers Position in Definitive Healthcare Corp. $DH

Pinnacle Wealth Management Advisory Group LLC reduced its stake in Definitive Healthcare Corp. (NASDAQ:DH) by 50.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 130,000 shares of the company’s stock after selling 130,000 shares during the quarter. Pinnacle Wealth Management Advisory Group LLC owned about 0.09% of Definitive Healthcare worth $507,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. Teacher Retirement System of Texas bought a new position in shares of Definitive Healthcare in the 1st quarter worth $376,000. Cerity Partners LLC purchased a new position in Definitive Healthcare in the first quarter worth $56,000. Victory Capital Management Inc. increased its stake in Definitive Healthcare by 519.3% in the first quarter. Victory Capital Management Inc. now owns 223,941 shares of the company’s stock valued at $647,000 after acquiring an additional 187,780 shares during the last quarter. Allianz Asset Management GmbH raised its position in Definitive Healthcare by 70.0% during the first quarter. Allianz Asset Management GmbH now owns 42,000 shares of the company’s stock valued at $121,000 after purchasing an additional 17,300 shares in the last quarter. Finally, Pinnacle Associates Ltd. bought a new stake in Definitive Healthcare during the first quarter worth about $751,000. 98.67% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Robert W. Baird set a $4.00 price objective on Definitive Healthcare in a research report on Friday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Definitive Healthcare in a research report on Wednesday, October 8th. William Blair raised shares of Definitive Healthcare to a “strong-buy” rating in a research note on Thursday. Finally, Stifel Nicolaus upped their price objective on shares of Definitive Healthcare from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Definitive Healthcare presently has a consensus rating of “Hold” and a consensus price target of $4.28.

Definitive Healthcare Stock Performance

Shares of NASDAQ:DH opened at $2.93 on Monday. The company has a current ratio of 1.65, a quick ratio of 1.65 and a debt-to-equity ratio of 0.39. The company has a 50-day moving average price of $3.46 and a 200-day moving average price of $3.58. The company has a market cap of $419.40 million, a price-to-earnings ratio of -1.75 and a beta of 1.61. Definitive Healthcare Corp. has a 12 month low of $2.15 and a 12 month high of $5.68.

Definitive Healthcare (NASDAQ:DH) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.01. The business had revenue of $60.05 million during the quarter, compared to analysts’ expectations of $59.51 million. Definitive Healthcare had a positive return on equity of 3.14% and a negative net margin of 77.88%. Definitive Healthcare has set its FY 2025 guidance at 0.230-0.240 EPS. Q4 2025 guidance at 0.050-0.060 EPS. As a group, equities analysts anticipate that Definitive Healthcare Corp. will post 0.16 EPS for the current year.

Definitive Healthcare Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.